A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Our lead drug candidate under development is oral (Z)-endoxifen, which we are developing for both the prevention and treatment of breast cancer and other therapeutic areas. Our business strategy is to advance our programs through clinical studies, including potentially with partners, and opportunistically add programs in areas of high unmet medical need through acquisition, minority investment, collaboration or internal development. (Z)-endoxifen is an active metabolite of tamoxifen, which is an FDA-approved drug to treat and prevent breast cancer. Tamoxifen is a "pro-drug," in that it must be metabolized into active components or metabolites to be effective.
| Metric | TTM | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -30M | -6.4M | -16M | -15M | -11M | -5.1M |
| EPS | $-3.45 | $-388.80 | $-22,437.00 | $-1,647.00 | $-5,778.00 | $-3,429.00 |
| Free Cash Flow | -26M | -5.4M | -14M | -11M | -9.1M | -4.0M |
| ROIC | -44.7% | -203.3% | -269.4% | -81.7% | -101.7% | -77.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.34 | 0.67 | 0.01 | 0.00 | 0.32 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -33M | -8.0M | -13M | -12M | -11M | -5.1M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -60.6% | -205.6% | -421.2% | -154.3% | -101.7% | -98.2% |
| Shares Outstanding | 9M | 0M | 0M | 0M | 0M | 0M |
| Metric | 2012 | 2013 | 2014 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 2.0M | 4.7M | 1.1M | 2.4M | 770K | 18M |
| SG&A | 9.4M | 8.6M | 8.1M | 8.8M | 6.5M | 14M |
| EBIT | -5.1M | -11M | -12M | -13M | -8.0M | -33M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -5.1M | -11M | -15M | -16M | -6.4M | -30M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 158K | 2.4M | 0 | 719K | 0 |
| Returns on Capital | ||||||
| ROIC | -77.4% | -101.7% | -81.7% | N/M | N/M | -44.7% |
| ROE | -98.2% | -101.7% | -154.3% | -421.2% | -205.6% | -60.6% |
| ROA | -74.4% | -89.8% | -124.6% | -252.4% | -153.7% | -52.0% |
| Cash Flow | ||||||
| Op. Cash Flow | -3.9M | -8.8M | -11M | -14M | -5.4M | -26M |
| Free Cash Flow | -4.0M | -9.1M | -11M | -14M | -5.4M | -26M |
| Owner Earnings | -4.2M | -11M | -12M | -15M | -6.6M | -29M |
| CapEx | 105K | 244K | 159K | 131K | 9K | 16K |
| Maint. CapEx | 131K | 473K | 480K | 273K | 303K | 16K |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 131K | 473K | 480K | 273K | 303K | 16K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 122K | 1.4M | 556K | 840K | 876K | 2.9M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | N/A | -13M | -17M | N/A | N/A | -104M |
| Cash & Equiv. | 1.7M | 6.3M | 8.5M | 3.7M | 3.0M | 104M |
| Long-Term Debt | N/A | 6K | 49K | N/A | N/A | N/A |
| Debt/Equity | 0.32 | 0.00 | 0.01 | 0.67 | 0.34 | 0.00 |
| Interest Coverage | -129.4 | -272.8 | -771.8 | -40248.0 | N/A | N/A |
| Equity | 5.2M | 11M | 9.5M | 3.7M | 3.1M | 50M |
| Total Assets | 6.8M | 12M | 12M | 6.2M | 4.1M | 58M |
| Total Liabilities | 1.7M | 1.4M | 2.3M | 2.5M | 1.0M | 8.2M |
| Intangibles | 4.6M | 4.4M | 1.9M | 1.7M | 640K | 640K |
| Retained Earnings | -9.7M | -21M | -35M | -51M | -57M | -236M |
| Working Capital | 339K | 5.4M | 7.1M | 1.8M | 2.2M | 47M |
| Current Assets | 2.0M | 6.8M | 9.3M | 4.3M | 3.3M | 56M |
| Current Liabilities | 1.7M | 1.4M | 2.3M | 2.5M | 1.0M | 8.2M |
| Per Share Data | ||||||
| EPS | -3,429.00 | -5,778.00 | -1,647.00 | -22,437.00 | -388.80 | -3.45 |
| Owner EPS | -458.94 | -1,142.54 | -1,302.51 | -21,448.57 | -37.07 | -3.39 |
| Book Value | 572.03 | 1,127.12 | 1,067.23 | 5,326.88 | 17.52 | 5.78 |
| Cash Flow/Share | -431.05 | -938.77 | -1,186.04 | -19,864.45 | -30.40 | -3.50 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.0M | 0.0M | 0.0M | 0.0M | 0.2M | 8.6M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -1.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 10.5 | 3.5 | 4.8 | 2.7 | N/A | 0.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -7.4% | -24.6% | -23.7% | -140.4% | N/A | -57.1% |
| Market Cap | 54M | 37M | 45M | 10M | 0 | 46M |
| Avg. Price | 12,034.29 | 13,429.07 | 4,391.86 | 3,108.32 | 0.00 | 5.35 |
| Year-End Price | 11,826.00 | 6,453.00 | 5,076.00 | 945.00 | 0.00 | 5.35 |
ATOSSA THERAPEUTICS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
ATOSSA THERAPEUTICS, INC. (ATOS) has a 5-year average return on invested capital (ROIC) of -86.9%. This is below average and may indicate limited pricing power.
ATOSSA THERAPEUTICS, INC. (ATOS) has a market capitalization of $46M. It is classified as a small-cap stock.
ATOSSA THERAPEUTICS, INC. (ATOS) does not currently pay a regular dividend.
ATOSSA THERAPEUTICS, INC. (ATOS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ATOSSA THERAPEUTICS, INC. (ATOS) generated $-5 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ATOSSA THERAPEUTICS, INC. (ATOS) has a debt-to-equity ratio of 0.34. This indicates a conservatively financed balance sheet.
ATOSSA THERAPEUTICS, INC. (ATOS) reported earnings per share (EPS) of $-388.80 in its most recent fiscal year.
ATOSSA THERAPEUTICS, INC. (ATOS) has a return on equity (ROE) of -205.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 5 years of financial data for ATOSSA THERAPEUTICS, INC. (ATOS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ATOSSA THERAPEUTICS, INC. (ATOS) has a book value per share of $17.52, based on its most recent annual SEC filing.